Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Atypical Chemokine Receptor 3 Market by Type (CCX-650, JT-07, POL-6926, CCX-771, Others), By Application (Autoimmune Diorders, Atherosclerosis, Crohn’s Disease, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Atypical Chemokine Receptor 3 Market by Type (CCX-650, JT-07, POL-6926, CCX-771, Others), By Application (Autoimmune Diorders, Atherosclerosis, Crohn’s Disease, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 133883 3300 Pharma & Healthcare 377 244 Pages 5 (36)

Market Overview:

The global atypical chemokine receptor 3 market is expected to grow from USD XX million in 2018 to USD XX million by 2030, at a CAGR of XX%. The growth of the market can be attributed to the increasing prevalence of autoimmune disorders, atherosclerosis, and Crohn's disease. Moreover, the increasing demand for novel therapies for treating these diseases is also contributing to the growth of the market. However, stringent regulatory requirements and high cost associated with novel therapies are restraining the growth of this market. The global atypical chemokine receptor 3 market is segmented on the basis of type, application, and region. On the basis of type, it is divided into CCX-650 JT-07 POL-6926 CCX-771 Others. On the basis on application it is classified into autoimmune disorders such as rheumatoid arthritis psoriasis lupus erythematosus multiple sclerosis systemic lupus erythematosus Sjogren's syndrome myasthenia gravis chronic obstructive pulmonary disease (COPD) asthma atherosclerosis crohn's disease others which include cancer renal failure transplant rejection etc. Geographically it has been analyzed across North America Latin America Europe Asia Pacific and Middle East & Africa regions.

Global Atypical Chemokine Receptor 3 Industry Outlook

Product Definition:

Atypical chemokine receptor 3 (ACKR3) is a protein that in humans is encoded by the ACKR3 gene. The protein encoded by this gene is a member of the G-protein coupled receptor family. It binds to atypical chemokines, which are chemokines that are not CCR5 or CXCR4 ligands. The function of this receptor is unknown.


CCX-650 is a novel oral drug developed by Cipla, Inc. for the treatment of atopic dermatitis and psoriasis. The drug has completed phase II clinical trials and is expected to be launched in the market during 2015-2016. CCX- 650 was granted breakthrough therapy approval by FDA in 2014 for treating patients with moderate to severe plaque psoriasis, which may give this market a significant boost during the forecast period.


JT-07 is a humanized monoclonal antibody that binds to the AHR (Atypical chemokine receptor). JT-07 was discovered by chance when researchers were studying an immune cell involved in the processing of interleukin (IL) - 1. The antibody was found to block the IL - 1 signal and thus blocked tumor growth in animal models.

Application Insights:

The autoimmune disorders segment dominated the global atypical chemokine receptor 3 market in terms of revenue in 2017. This is due to the rising prevalence of atopic dermatitis, allergic rhinitis, and asthma among other diseases. For instance, according to a study published by NCBI in 2018, it was found that around 40% of people across the globe have some form of allergy or intolerance which was earlier estimated to be around 10%. Furthermore, another factor contributing towards growth is increasing R&D for developing drugs targeting CCK-R3 receptors owing to its promising applications such as treatment for gastrointestinal conditions and cancer.

Atherosclerosis accounted for a significant share owing to high product usage during surgeries on arteries & veins as well as heart valves removal procedures. In addition, growing awareness about this disease coupled with rising patient visits regarding cardiovascular diseases (CVDs) worldwide is expected fuel demand over the forecast period.

Regional Analysis:

North America dominated the global atypical chemokine receptor 3 market in 2017. The presence of key players, favorable reimbursement policies, and increasing R&D activities are some of the factors responsible for its large share. For instance, in February 2016 FK-4696 was granted accelerated approval by the U.S FDA for treatment of moderate to severe ulcerative colitis due to CD19+ cancer stem cells (CSC) driven disease progression as well as maintenance therapy use after completion of 6 months or more course of initial immunotherapy drug therapy regimen.

Asia Pacific region is anticipated to grow with fastest CAGR during the forecast period owing to rising incidences associated with various diseases such as Crohn’s disease and ulcerative colitis which are driven by an unhealthy lifestyle.

Growth Factors:

  • Increasing prevalence of autoimmune diseases: The increasing prevalence of autoimmune diseases is one of the key growth drivers for the Atypical Chemokine Receptor 3 market. According to a study by the American Autoimmune Related Diseases Association (AARDA), around 50 million Americans are affected by autoimmune diseases, which is approximately 20% of the population. This number is expected to increase in the coming years due to factors such as changing lifestyles and environmental pollution. This will create a high demand for Atypical Chemokine Receptor 3 products and boost the growth of the market.
  • Rising awareness about atypical chemokines: There is a growing awareness among people about atypical chemokines and their role in immune system regulation. This has led to an increase in research activities on these molecules, which is likely to result in new product launches in this market over the next few years.
  • Growing demand for personalized medicine: The trend towards personalized medicine is another major driver for this market as it helps target therapies according to individual patient needs instead of using generic treatments that may not be effective for all patients suffering from a particular disease condition or disorder .This trend will lead to increased demand for Atypical Chemokine Receptor 3 products over time, boosting growth prospects for this market segment..

Scope Of The Report

Report Attributes

Report Details

Report Title

Atypical Chemokine Receptor 3 Market Research Report

By Type

CCX-650, JT-07, POL-6926, CCX-771, Others

By Application

Autoimmune Diorders, Atherosclerosis, Crohn's Disease, Others

By Companies

ChemoCentryx Inc, Jyant Technologies Inc, Polyphor Ltd, ...

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global Atypical Chemokine Receptor 3 Market Report Segments:

The global Atypical Chemokine Receptor 3 market is segmented on the basis of:


CCX-650, JT-07, POL-6926, CCX-771, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Autoimmune Diorders, Atherosclerosis, Crohn's Disease, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. ChemoCentryx Inc
  2. Jyant Technologies Inc
  3. Polyphor Ltd
  4. ...

Global Atypical Chemokine Receptor 3 Market Overview

Highlights of The Atypical Chemokine Receptor 3 Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. CCX-650
    2. JT-07
    3. POL-6926
    4. CCX-771
    5. Others
  1. By Application:

    1. Autoimmune Diorders
    2. Atherosclerosis
    3. Crohn's Disease
    4. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Atypical Chemokine Receptor 3 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Atypical Chemokine Receptor 3 Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

Atypical Chemokine Receptor 3 (ACR3) is a receptor that binds to atypical chemokines. These are small proteins that play an important role in the immune system.

Some of the major players in the atypical chemokine receptor 3 market are ChemoCentryx Inc, Jyant Technologies Inc, Polyphor Ltd.

1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Atypical Chemokine Receptor 3 Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Atypical Chemokine Receptor 3 Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Atypical Chemokine Receptor 3 Market - Supply Chain
   4.5. Global Atypical Chemokine Receptor 3 Market Forecast
      4.5.1. Atypical Chemokine Receptor 3 Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Atypical Chemokine Receptor 3 Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Atypical Chemokine Receptor 3 Market Absolute $ Opportunity

5. Global Atypical Chemokine Receptor 3 Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Type
      5.3.1. CCX-650
      5.3.2. JT-07
      5.3.3. POL-6926
      5.3.4. CCX-771
      5.3.5. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Atypical Chemokine Receptor 3 Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Application
      6.3.1. Autoimmune Diorders
      6.3.2. Atherosclerosis
      6.3.3. Crohn's Disease
      6.3.4. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Atypical Chemokine Receptor 3 Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Atypical Chemokine Receptor 3 Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Atypical Chemokine Receptor 3 Demand Share Forecast, 2019-2029

9. North America Atypical Chemokine Receptor 3 Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Application
      9.4.1. Autoimmune Diorders
      9.4.2. Atherosclerosis
      9.4.3. Crohn's Disease
      9.4.4. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Type
      9.7.1. CCX-650
      9.7.2. JT-07
      9.7.3. POL-6926
      9.7.4. CCX-771
      9.7.5. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Atypical Chemokine Receptor 3 Demand Share Forecast, 2019-2029

10. Latin America Atypical Chemokine Receptor 3 Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Application
      10.4.1. Autoimmune Diorders
      10.4.2. Atherosclerosis
      10.4.3. Crohn's Disease
      10.4.4. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Type
      10.7.1. CCX-650
      10.7.2. JT-07
      10.7.3. POL-6926
      10.7.4. CCX-771
      10.7.5. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Atypical Chemokine Receptor 3 Demand Share Forecast, 2019-2029

11. Europe Atypical Chemokine Receptor 3 Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Application
      11.4.1. Autoimmune Diorders
      11.4.2. Atherosclerosis
      11.4.3. Crohn's Disease
      11.4.4. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Type
      11.7.1. CCX-650
      11.7.2. JT-07
      1.7.3. POL-6926
      11.7.4. CCX-771
      11.7.5. Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Atypical Chemokine Receptor 3 Demand Share, 2019-2029

12. Asia Pacific Atypical Chemokine Receptor 3 Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Application
      12.4.1. Autoimmune Diorders
      12.4.2. Atherosclerosis
      12.4.3. Crohn's Disease
      12.4.4. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Type
      12.7.1. CCX-650
      12.7.2. JT-07
      12.7.3. POL-6926
      12.7.4. CCX-771
      12.7.5. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Atypical Chemokine Receptor 3 Demand Share, 2019-2029

13. Middle East & Africa Atypical Chemokine Receptor 3 Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Application
      13.4.1. Autoimmune Diorders
      13.4.2. Atherosclerosis
      13.4.3. Crohn's Disease
      13.4.4. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Atypical Chemokine Receptor 3 Market Size and Volume Forecast by Type
      13.7.1. CCX-650
      13.7.2. JT-07
      13.7.3. POL-6926
      13.7.4. CCX-771
      13.7.5. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Atypical Chemokine Receptor 3 Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Atypical Chemokine Receptor 3 Market: Market Share Analysis
   14.2. Atypical Chemokine Receptor 3 Distributors and Customers
   14.3. Atypical Chemokine Receptor 3 Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. ChemoCentryx Inc Overview Financials Developments Strategic Outlook
      14.4.2. Jyant Technologies Inc Overview Financials Developments Strategic Outlook
      14.4.3. Polyphor Ltd Overview Financials Developments Strategic Outlook
      14.4.4. ... Overview Financials Developments Strategic Outlook
      14.4.5. COMPANY5 Overview Financials Developments Strategic Outlook
      14.4.6. COMPANY6 Overview Financials Developments Strategic Outlook
      14.4.7. COMPANY7 Overview Financials Developments Strategic Outlook
      14.4.8. COMPANY8 Overview Financials Developments Strategic Outlook
      14.4.9. COMPANY9 Overview Financials Developments Strategic Outlook
      14.4.10. COMPANY 10 Overview Financials Developments Strategic Outlook
      14.4.11. COMPANY 11 Overview Financials Developments Strategic Outlook
      14.4.12. COMPANY 12 Overview Financials Developments Strategic Outlook
      14.4.13. COMPANY 13 Overview Financials Developments Strategic Outlook
      14.4.14. COMPANY 14 Overview Financials Developments Strategic Outlook
      14.4.15. COMPANY 15 Overview Financials Developments Strategic Outlook
      14.4.16. COMPANY 16 Overview Financials Developments Strategic Outlook
      14.4.17. COMPANY 17 Overview Financials Developments Strategic Outlook
      14.4.18. COMPANY 18 Overview Financials Developments Strategic Outlook
      14.4.19. COMPANY 19 Overview Financials Developments Strategic Outlook
      14.4.20. COMPANY 20 Overview Financials Developments Strategic Outlook

Our Trusted Clients

Contact Us